Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
O15409
UPID:
FOXP2_HUMAN
Alternative names:
CAG repeat protein 44; Trinucleotide repeat-containing gene 10 protein
Alternative UPACC:
O15409; A0AUV6; A4D0U8; A6NNW4; B4DLD9; Q6ZND1; Q75MJ3; Q8IZE0; Q8N0W2; Q8N6B7; Q8N6B8; Q8NFQ1; Q8NFQ2; Q8NFQ3; Q8NFQ4; Q8TD74
Background:
Forkhead box protein P2, also known as CAG repeat protein 44 or Trinucleotide repeat-containing gene 10 protein, plays a pivotal role in the development of speech and language. It functions as a transcriptional repressor, crucial for lung epithelium differentiation, and contributes to neural, gastrointestinal, and cardiovascular tissue development. Additionally, it regulates synapse formation by controlling SRPX2 levels.
Therapeutic significance:
Linked to Speech-language disorder 1, Forkhead box protein P2's involvement in orofacial dyspraxia and language processing deficits highlights its potential as a target for therapeutic intervention. Understanding its role could pave the way for novel treatments for speech and language disorders.